TENX Tenax Therapeutics Inc.

0.44
+0.02  (4%)
Previous Close 0.42
Open 0.44
Price To book 1.10
Market Cap 12424080
Shares 28,236,546
Volume 373,892
Short Ratio 4.02
Av. Daily Volume 541,842

SEC filingsSee all SEC filings

  1. 8-K - Current report 171081531
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018535
  3. 8-K - Current report 17990729
  4. 8-K - Current report 17914088
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 17830776

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b trial did not meet primary endpoint.
Levosimendan
Septic shock
Phase 3 top line data released January 31, 2017 - primary endpoints not met. Met with FDA May 10, 2017 to discuss potential NDA submission.
Levosimendan
Reduce the incidence of low cardiac output syndrome during cardiac surgery

Latest News

  1. TENX: FDA Response on Levosimendan
  2. Tenax Therapeutics Provides Regulatory Update on Levosimendan
  3. Tenax Meets with FDA to Discuss Positive Mortality Data and Potential Levosimendan NDA Submission
  4. Tenax Therapeutics Announces Review of Strategic Alternatives and Business Update
  5. TENX: 2016 Results; Subgroup Analysis Shows CABG Survival Benefit
  6. Tenax Therapeutics Announces Year-End 2016 Financial Results and Provides Corporate Update
  7. Investor Network Invites You to the Tenax Therapeutics Fiscal Year 2016 Business Review and Update Conference Call and Webcast on Tuesday, March 21, 2017
  8. Tenax Therapeutics to Discuss Year-End 2016 Financial Results and Provide Business Update
  9. TENX: Tenax Reports LEVO-CTS Topline Results
  10. Under Armour, Rite Aid Fall into Tuesday’s 52-Week Low Club
  11. Tenax Therapeutics Announces Top-Line Results From Phase 3 LEVO-CTS Trial in Cardiac Surgery
  12. Biotech M&A Activity Expected to Rise in 2017: Latest Reports on Tenax Therapeutics and ZIOPHARM Oncology
  13. Tenax Therapeutics Inc (TENX) Might Be A Discount Opportunity Ahead Of January Release
  14. Tenax Therapeutics, Inc. Review of Clinical Trials and Financials
  15. Is KemPharm Inc (KMPH) A Good Stock To Buy?
  16. TENX: LEVO-CTS Enrolment Complete; Anticipate January Topline Readout
  17. Tenax Therapeutics Announces Completion of Enrollment for Phase 3 LEVO-CTS Trial in Cardiac Surgery
  18. Tenax Therapeutics Announces Third Quarter 2016 Financial Results and Provides Corporate Update

SEC Filings

  1. 8-K - Current report 171081531
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018535
  3. 8-K - Current report 17990729
  4. 8-K - Current report 17914088
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 17830776
  6. DEF 14A - Other definitive proxy statements 17796746
  7. 8-K - Current report 17750549
  8. 8-K - Current report 17698778
  9. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17694968
  10. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17612247